Adial Pharmaceuticals, Inc. has been granted a 180 calendar day extension by Nasdaq to regain compliance with the Minimum Bid Price Rule.
The extension was given following the expiration of the initial 180 calendar day period on September 1, 2025.
The Company now has until March 2, 2026, to meet the Minimum Bid Price Requirement.
Extension Granted
Adial Pharmaceuticals received a 180-day extension from Nasdaq to comply with the minimum bid price requirement.
Compliance Deadline
The Company has until March 2, 2026, to maintain a closing bid price of at least $1.00 per share for ten consecutive business days.
Trading Symbol
Shares of Adial Pharmaceuticals will continue to trade on the Nasdaq Capital Market under the symbol "ADIL."
- Adial Pharmaceuticals is focused on developing therapies for addiction and related disorders.
- The Company's lead investigational new drug product, AD04, has shown promising results in a Phase 3 clinical trial for Alcohol Use Disorder.
- AD04 is being developed as a treatment for other addictive disorders such as Opioid Use Disorder, gambling, and obesity.
Adial Pharmaceuticals remains committed to regaining compliance with the Nasdaq's minimum bid price requirement and continuing its development of treatments for addictions and related disorders.